Comment: A devastating setback for MND research: Why NICE needs to reconsider its approach to tofersen
Professor Dame Pamela Shaw, Director of the ºù«Ӱҵ Institute for Translational Neuroscience, discusses NICE's refusal to classify the MND drug tofersen, as a treatment for a highly specialised condition, rather than just a standard drug.